Acute kidney injury ‘uncommon’ but unpredictable on tenofovir and ritonavir

No excess risk of fracture seen on tenofovir or any other HIV drug

Gus Cairns
Published: 27 July 2017

Doctors need to monitor patients regularly for kidney function if they are taking tenofovir disoproxil, especially if combined with ritonavir, the 9th International AIDS Society Conference on HIV Science (IAS 2017) heard this week.

Fanconi syndrome is an acute type of kidney failure caused by leakage out of the blood into the urine of substances that should normally be reabsorbed: phosphates (which help build bone), amino acids and bicarbonate, which raises the acidity of the blood (acidosis) to dangerous levels.

“All these cases could have been spotted with a cheap urine dipstick test at every HIV checkup.” Dr Nicholas Medland

Dr Nicholas Medland of Monash University in Melbourne, Australia told delegates that Fanconi syndrome was “uncommon, but not rare” with 1.25% (one in 80) of his cohort of patients developing it within a ten-year period. Importantly, it could appear unexpectedly, in patients with no characteristics linked to kidney disease.

In another presentation, Dominique Costagliola of the French national medical research agency INSERM told delegates she had found no association between tenofovir, or any other HIV drug, and the risk of bone fractures of the type associated with low bone mineral density.

Fanconi syndrome, tenofovir and ritonavir

Dr Medland studied a cohort of 1044 patients who started and continued taking tenofovir disoproxil between 2002 and 2016, 398 of whom were also taking ritonavir as a booster for protease inhibitor drugs.

Their average age was 38 (ritonavir takers 41) and 88.5% were male and 75% gay men. The average time taking tenofovir was 3.5 years, or four years in those also taking ritonavir.

One average, patients had normal kidney function when they started tenofovir (eGFR = 106) and only 2.5% had kidney malfunction as defined by an eGFR below 50 (1.6% of those also taking ritonavir).

There were 13 cases of Fanconi syndrome in 1044 patients (1.25%) and the annual incidence was 1 case in 920 patients per year (0.11%). The average time patients spent on tenofovir before Fanconi syndrome developed was 5.5 years.

Importantly, Fanconi syndrome was not associated with any predisposing factor for kidney dysfunction: age, sex, high blood pressure or lipids, diabetes, viral hepatitis, low CD4 count or lowest-ever count, of baseline low eGFR. “These were well patients in whom Fanconi syndrome developed suddenly”, said Medland.

Nine out of the 13 cases were also taking ritonavir, and the annual incidence in these patients was 1 in 182 patients per year (0.55%). Ritonavir co-administration raised the risk of Fanconi syndrome nearly fivefold (adjusted hazard ratio, 4.71).

“All these cases could have been spotted with a cheap urine dipstick test at every HIV checkup,” said Dr Medland, urging continued monitoring even in patients with perfectly normal kidney function.

Tenofovir, protease inhibitors and fractures

Tenofovir disoproxil has been associated with low bone mineral density and osteoporosis, as have protease inhibitors, but does this translate into a higher risk of bone fractures?

To answer this question, Dominique Costagliola looked at the French HIV Hospital Database, which contains the majority of people with HIV attending clinics in the country. Between 2000 and 2010, she found 1026 fractures in 62,776 patients. However, only 261 of these had evidence of “low energy” fractures, i.e. fractures associated with impacts that should not normally break bones, such as falls from standing height, and at skeletal sites where osteoporosis most often occurred.

She matched 254 of these patients with 376 control patients who had the same age, sex, length of HIV diagnosis, and if possible attendance at the same clinic. The average age of these 630 patients was 49, two-thirds were men, about two-thirds were diagnosed before 1997, and about 40% started antiretroviral therapy (ART) before 1997. Seventy per cent started ART before 2001.

There were 38 control patients and eight with fractures who were never on ART between 2000 and 2010.

Patients with fractures were more likely to be men who have sex with men (34 vs 20%) and less likely to be sub-Saharan Africans (3.9 vs 11%). They were also more likely to be underweight (13 vs 6%; low body weight is a well-known risk factor for fracture), to have had a prior AIDS diagnosis (31 vs 20%), to have used medical steroids (9.8 vs 3.7%) and to drink more than two alcoholic drinks a day (24 vs 13%). Other factors, apart from existing osteoporosis (10 vs 2%), were not significant.

Costagliola then looked at the relationship between specific HIV drugs and the risk of fracture. In terms of whether drugs had been used at all, protease inhibitors were associated with a 67% increased risk of fracture, and the individual protease inhibitors atazanavir and lopinavir (in Kaletra) with a similar raised risk. In terms of duration of cumulative use, the only drug with a significant association with fracture was atazanavir.

However, in a model that adjusted for all other risk factors, no HIV drug was associated with the risk of fracture. Tenofovir was, in this model, associated with a 24% raised risk, but this was a trend rather than being statistically significant.

Efavirenz was associated with a 40% reduced risk of fracture in this model, but this again was only a trend rather than being statistically significant.

Costagliola said she had found no definite association between any ART drug and fracture, but also noted that because this was a patient group who had started ART early, only 9% had tenofovir in their first ART regime. Similar studies of cohorts starting ART later should therefore be done in the future to see if it is associated with fracture, especially as patients age.

References

Medland NA et al. Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxyl fumarate. 9th International AIDS Society Conference on HIV Science, Paris, abstract no MOPDB0102, July 2017.

View the abstract on the conference website.

Download the e-poster from the conference website.

Watch the webcast of this session YouTube.

Costagliola D et al. Impact of exposure to each antiretroviral treatment (ARV) on the risk of fracture in HIV-1-infected individuals: an analysis from FHDH ANRS CO4. 9th International AIDS Society Conference on HIV Science, Paris, abstract no WEAB0103, July 2017.

View the abstract on the conference website.

Download the presentation slides from the conference website.

Watch the webcast of this session on YouTube.

E-atlas

Australia

Find details of HIV services in Australia, the latest news from the country, and a selection of resources from local organisations.

Find out more about Australia >

E-atlas

France

Find details of HIV services in France, the latest news from the country, and a selection of resources from local organisations.

Find out more about France >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.